Annalisa Paviglianiti

Nov 20, 2024 | mdpi.com | Diana Martinez |Nicole Santoro |Annalisa Paviglianiti

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Apr 22, 2024 | onlinelibrary.wiley.com | Annalisa Paviglianiti |L'hospitalet de Llobregat

In their paper, the authors reported the impact of letermovir prophylaxis on cytomegalovirus (CMV) reactivation and resistance in both adult and paediatric patients who underwent umbilical cord blood transplantation (UCBT).1 They observed a significantly lower cumulative incidence of CMV reactivation at 180 days in those patients receiving letermovir compared to the historical control group.